{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-009363","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.028958+00:00","generated_at":"2026-06-15T03:33:59.933477+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Capricor Q1 2023 net loss $7.8M; HOPE-3 DMD trial interim analysis on track for Q4 2023","bullets":["Net loss $7.8M ($0.31 per share) flat YoY; revenue $3.0M from Nippon Shinyaku deal vs zero prior year.","Cash, equivalents and marketables $45.2M; runway into Q4 2024, excludes milestone payments.","HOPE-3 Phase 3 for CAP-1002 in DMD: 13 active sites, targeting full enrollment by H2 2023, interim analysis Q4 2023.","24-month HOPE-2 open-label extension data planned for presentation in Q2 2023.","Received $12M upfront from Japan partner Nippon Shinyaku; potential milestones up to ~$89M plus revenue share."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-009363","json":"https://secwatch.observer/filing/0001558370-23-009363.json","markdown":"https://secwatch.observer/filing/0001558370-23-009363.md","text":"https://secwatch.observer/filing/0001558370-23-009363.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023009363/0001558370-23-009363-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023009363/capr-20230511x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:33:59.933477+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ced5f94535e2f8ff73974e8349623899849e130","claim":"CAPRICOR THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: revenue approximately $3.0 million, net income approximately $7.8 million, or $0.31 per share, EPS $0.31 per share.","evidence_excerpt":"U.S. Exclusive Commercialization and Distribution Agreement received from Nippon Shinyaku in the first quarter of 2022. Revenues for the first quarter of 2023 were approximately $3.0 million compared with zero for the first quarter of 2022. Operating expenses: Total operating expenses for the first quarter of 2023 were approximately $11.2 million compared with","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837023009363/0001558370-23-009363-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"approximately $3.0 million"},{"label":"Net income","value":"approximately $7.8 million, or $0.31 per share"},{"label":"EPS","value":"$0.31 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}